"Isotretinoin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects.
| Descriptor ID |
D015474
|
| MeSH Number(s) |
D02.455.326.271.665.202.495.325 D02.455.426.392.368.367.379.249.700.325 D02.455.849.131.495.325 D23.767.261.700.325
|
| Concept/Terms |
Isotretinoin- Isotretinoin
- 13-cis-Retinoic Acid
- 13 cis Retinoic Acid
|
Below are MeSH descriptors whose meaning is more general than "Isotretinoin".
Below are MeSH descriptors whose meaning is more specific than "Isotretinoin".
This graph shows the total number of publications written about "Isotretinoin" by people in this website by year, and whether "Isotretinoin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 3 | 2 | 5 |
| 1995 | 2 | 2 | 4 |
| 1996 | 2 | 1 | 3 |
| 1997 | 3 | 0 | 3 |
| 1998 | 1 | 5 | 6 |
| 1999 | 2 | 1 | 3 |
| 2000 | 2 | 2 | 4 |
| 2001 | 3 | 2 | 5 |
| 2002 | 0 | 1 | 1 |
| 2003 | 3 | 4 | 7 |
| 2004 | 2 | 0 | 2 |
| 2005 | 1 | 1 | 2 |
| 2006 | 2 | 2 | 4 |
| 2007 | 1 | 4 | 5 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 4 | 1 | 5 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Isotretinoin" by people in Profiles.
-
Pityriasis Rubra Pilaris: An Updated Review of Clinical Presentation, Etiopathogenesis, and Treatment Options. Am J Clin Dermatol. 2024 Mar; 25(2):243-259.
-
Successful treatment of a child with MEK inhibitor-induced acneiform eruption with low-dose isotretinoin. Pediatr Dermatol. 2022 Jul; 39(4):646-647.
-
Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin. Int J Risk Saf Med. 2022; 33(1):65-76.
-
Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways. Br J Cancer. 2020 08; 123(4):568-579.
-
Retrospective case series of isotretinoin outcomes for acne in 393 female patients at Baylor College of Medicine during 2012-2016. J Am Acad Dermatol. 2020 05; 82(5):1218-1219.
-
Isotretinoin and Timing of Procedural Interventions: A Systematic Review With Consensus Recommendations. JAMA Dermatol. 2017 08 01; 153(8):802-809.
-
Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition. Cancer Chemother Pharmacol. 2015 Nov; 76(5):977-87.
-
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol. 2015 Feb; 17(2):266-73.
-
Reversal of skin aging with topical retinoids. Plast Reconstr Surg. 2014 Apr; 133(4):481e-490e.
-
Congenital neuroblastoma in a neonate with isotretinoin embryopathy. J Pediatr Hematol Oncol. 2014 Mar; 36(2):e75-7.